Firefly Neuroscience Inc Dossier - Source-backed chat

Firefly Neuroscience Inc

AIFFNASDAQ

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)-2.25

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.46Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $22.9M

Enterprise Value $13.7M

Shares Outstanding 15.7M diluted

Next Earnings Date14 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Firefly Neuroscience is a high-innovation, micro-cap medical technology company transitioning its FDA-cleared Brain Network Analytics (BNA) platform and Evoke System into a recurring subscription model. Backed by a massive, proprietary database of over 200,000 standardized EEG/ERP brain scans and a newly identified PTSD biomarker, the company possesses strong technological differentiation and high-throughput AI capabilities powered by NVIDIA GPU infrastructure. However, persistent operating losses, an accumulated deficit of $113.6 million, and negative operating cash flows present substantial going concern risks. While recent private placements have temporarily extended the cash runway, commercial execution and further non-dilutive capital access are critical before a more bullish stance can be justified.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

Commercial adoption of the BNA platform stalls due to tight clinical budgets or reimbursement hurdles. The company fails to secure additional financing on acceptable terms, and the going concern risk materializes, forcing severe cost-cutting that halts R&D and commercial expansion. Continued equity dilution from capital raises severely depresses the share price.

Base CaseCentral scenario

$1.8055%

The company continues to steadily expand its clinical footprint beyond 85 sites, maintaining sequential scan volume growth. Revenue scales gradually as the transition to the subscription/lease model takes hold, narrowing quarterly operating losses. Firefly relies on periodic, dilutive private placements and at-the-market equity programs to fund operations, keeping the stock trading near its current fair value range as it works toward operational break-even.

Bull CaseUpside scenario

$3.5025%

Rapid commercial adoption of the subscription-based Evoke System across U.S. clinical sites drives exponential recurring revenue growth. The newly discovered PTSD biomarker is successfully commercialized through the public-private partnership with the Department of Defense (War) and adopted by pharmaceutical companies as a primary efficacy endpoint in CNS clinical trials. Strategic collaboration with NVIDIA accelerates the launch of the world's first foundation model of the human brain, attracting a high-premium acquisition offer from a major medical device or digital health player.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary database of over 200,000 standardized EEG/ERP brain scans across 12+ neurological and psychiatric disorders, providing an unmatched data moat for AI training.
FDA 510(k)-cleared Evoke System and BNA software platform offer objective, measurable neurophysiological insights, shifting the paradigm away from subjective clinical questionnaires.
Active public-private partnership with the U.S. Department of Defense (War) for PTSD and Traumatic Brain Injury (TBI) assessment, validated by the discovery of a novel electrophysiological PTSD biomarker.
Strategic technology alignment, including acceptance into the NVIDIA Connect program and utilization of NVIDIA L40S GPU-accelerated infrastructure to build a brain foundation model.

Key Investment Risks

Substantial going concern risk highlighted by auditors, driven by recurring operating losses and an accumulated deficit of $113.6 million as of March 31, 2026.
High risk of shareholder dilution due to ongoing reliance on private placements, warrant exercises, and at-the-market equity programs to sustain operations.
Execution risk associated with transitioning the acquired Evoke business from one-time hardware sales to a recurring subscription/lease model.
Regulatory, privacy, and reimbursement complexities, including ongoing compliance with FDA, HIPAA, and GDPR frameworks.

Thesis Invalidation Triggers

Failure to secure additional financing or strategic partnerships before existing cash reserves are depleted.
A material decline in sequential EEG/ERP brain scan volumes or loss of active clinical partner sites.
Termination or lack of progress in the public-private partnership with the Department of Defense (War).
Inability to maintain compliance with Nasdaq listing requirements, including minimum bid price or public float thresholds.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.